閉場中RVOL 0.4xDV $626,21520日平均DV $2M?
Earnings 2027-03-1152W high -83.2%52W low +66.7%Fwd PER 0.4xMarket cap $5MAvg volume 2.2M
Company Overview
Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q3 | -1.14 | $722,000 | -$8M |
| 2026 Q2 | -1.33 | $411,000 | -$8M |
| 2026 Q1 | -1.05 | $1M | -$7M |
| 2025 Q4 | -1.04 | $1M | -$6M |
| 2025 Q3 | -1030.00 | $1M | -$3M |
| 2025 Q2 | 615.00 | $1M | -$6M |
| 2025 Q1 |
Beta access -> Sign in with an invite code